Podcasts about rcc

Message from Terry Williams on September 14, 2025

ゲスト：RCC中国放送・家森亮記者 2025年9月10日（水）「FrontLine Session」より。 発信型ニュース・プロジェクト「荻上チキ・Session」 ★月～金曜日　17:00～20:00　TBSラジオで生放送 パーソナリティ：荻上チキ、南部広美 番組HP：荻上チキ・Session 番組メールアドレス：ss954@tbs.co.jp 番組Xアカウント：@Session_1530 ハッシュタグは #ss954 Learn more about your ad choices. Visit megaphone.fm/adchoices

Listen as pulmonologist Peter Dicpinigaitis discusses his approach to the diagnosis and management of patients with refractory chronic cough in the context of a clinically relevant case and provides insights regarding emerging therapies.PresenterPeter Dicpinigaitis, MDProfessor of MedicineAlbert Einstein College of MedicineDivision of Critical Care MedicineMontefiore Medical CenterDirector, Montefiore Cough CenterBronx, New YorkLink to full program:https://bit.ly/4kweynG

Dr. Pedro Barata and Dr. Rana McKay discuss the integration of innovative advances in molecular imaging and therapeutics to personalize treatment for patients with renal cell and urothelial carcinomas. TRANSCRIPT Dr. Pedro Barata: Hello, I'm Dr. Pedro Barata, your guest host of By the Book, a podcast series featuring insightful conversations between authors and editors of the ASCO Educational Book. I'm a medical oncologist at University Hospitals Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also an associate editor of the ASCO Educational Book. Now, we all know the field of genitourinary cancers (GU) is evolving quite rapidly, and we have new innovations in molecular imaging as well as targeted therapeutics. Today's episode will be exploring novel approaches that are transforming the management of renal cell and urothelial carcinomas and also their potential to offer a more personalized treatment to patients. For that, joining for today's discussion is Dr. Rana McKay, a GU medical oncologist and professor at University of California San Diego. Dr. McKay will discuss her recently published article titled, “Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor-Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas.”  Our full disclosures are available in the transcript of this episode.  And with that, Rana McKay, great to have you on the podcast today. Dr. Rana McKay: Oh, thank you so much, Dr. Barata. It's really wonderful to be here with you. So, thanks for hosting. Dr. Pedro Barata: No, thanks for taking the time, and I'm looking forward to this conversation. And by the way, let me start by saying congrats on a great article in the Educational Book. Really super helpful paper. I'm recommending it to a lot of the residents and fellows at my own institution. I would like to first ask you to kind of give our listeners some context of how novel approaches in the molecular imaging as well as targeted therapeutics are actually changing the way we're managing patients with GU, but specifically with renal cell carcinoma and urothelial carcinoma. So, what are the areas you would call out as like being big areas for innovation in this context, and why are they important? Dr. Rana McKay: Very good question. And I think this is really what this article highlights. It highlights where are we going from an imaging diagnostics standpoint? Where are we going from a therapeutic standpoint? And I think if we have to step back, from the standpoint of diagnostics, we've seen PET imaging really transform diagnostics in prostate cancer with the advent of PSMA PET imaging, and now PSMA PET imaging is used as a biomarker for selection for theranostics therapy. And so, we're starting to see that enter into the RCC landscape, enter into the urothelial cancer landscape to a lesser extent. And I think it's going to potentially be transformative as these tools get more refined. I think when we think about therapeutics, what's been transformative most recently in the renal cell carcinoma landscape has been the advent of HIF2α inhibition to improve outcomes for patients. And we have seen the approval of belzutifan most recently that has reshaped the landscape. And now there's other HIF2α inhibitors that are being developed that are going to be further important as they get refined. And lastly, I think when we think about urothelial carcinoma, the greatest transformation to treatment in that context has been the displacement of cisplatin and platinum-based chemotherapy as a frontline standard with the combination of enfortumab vedotin plus pembrolizumab. And we've seen antibody-drug conjugates really reshape treatment and tremendously improve outcomes for patients. So, I think those are the three key areas of interest. Dr. Pedro Barata: So with that, let's focus first on the imaging and then we'll get to the therapeutic area. So, we know there's been a paradigm shift, really, when prostate-specific targets emerged as tracers for PET scanning. And so, we now commonly use prostate-specific membrane antigen, or PSMA-based PET scanning, and really transform how we manage prostate cancer. Now, it appears that we're kind of seeing a similar wave in renal cell carcinoma with the new radiotracer against the target carbonic anhydrase IX. What can you tell us about this? And is this going to be available to us anytime soon? And how do you think that might potentially change the way we're managing patients with RCC today? Dr. Rana McKay: First, I'll step back and say that in the context of PSMA PET imaging, we have actually been able to better understand RCC as well. So, we know that PSMA is expressed in the neovasculature of tumors, and it can actually be used to detect renal cell carcinoma tumors. It has a detection rate of about 84% when used for detection. And so, you know, I don't think it's just restricted to carbonic anhydrase IX, but we will talk about that. So, PSMA expressed in the neovasculature has a detection rate of around 84%, particularly if we're looking at clear cell RCC. CAlX is overexpressed in clear cell RCC, and it's actually used in diagnosing renal cell carcinoma when we think of CAlX IHC for diagnosing clear cell RCC. And now there are CAlX PET tracers. The first foray was with the ZIRCON study that was actually an interestingly designed study because it was designed to detect the likelihood of PET imaging to identify clear cell RCC. So, it was actually used in the early diagnostics setting when somebody presents with a renal mass to discriminate that renal mass from a clear cell versus a non-clear cell, and it was a positive study. But when I think about the potential application for these agents, you know, I think about the entire landscape of renal cell carcinoma. This is a disease that we do treat with metastasis-directed therapy. We have certainly seen patients who've undergone metastasectomy have long, durable remissions from such an approach. And I think if we can detect very early onset oligometastatic disease where a metastasis-directed therapy or SABR could be introduced - obviously tested in a trial to demonstrate its efficacy - I think it could potentially be transformative. Dr. Pedro Barata: Wonderful. It's a great summary, and I should highlight you are involved in some of those ongoing studies testing the performance of this specific PET scanning for RCC against conventional imaging, right? And to remind the listeners, thus far, for the most part, we don't really do FDG-PET for RCC. There are some specific cases we do, but in general, they're not a standard scanning. But maybe that will change in the future. Maybe RCC will have their own PSMA-PET. And to your point, there's also emerging data about the role of PSMA-PET scanning in RCC as well, as you very elegantly summarized. Wonderful. So, let me shift gears a little bit because you did, in your introduction, you did highlight a novel MOA that we have in renal cell carcinoma, approved for use, initially for VHL disease, and after that for sporadic clear cell renal cell carcinoma. We're talking about hypoxia-inducible factor 2-alpha inhibitors, or HIF2α inhibitors, such as belzutifan. But there's also others coming up. So, as a way to kind of summarize that, what can you tell us about this breakthrough in terms of therapeutic class, this MOA that got to our toolbox of options for patients with advanced RCC? Tell us a little bit what is being utilized currently in the management of advanced RCC. And where do you see the future going, as far as, is it moving early on? Is it getting monotherapy versus combinations? Maybe other therapies? What are your thoughts about that? What can you tell us about it? Dr. Rana McKay: Belzutifan is a first-in-class HIF2α inhibitor that really established clinical validation for HIF2α as a therapeutic target. When we think about the activity of this agent, the pivotal LITESPARK-005 trial really led to the approval of belzutifan in patients who were really heavily pretreated. It was patients who had received prior IO therapy, patients who had received prior VEGF-targeted therapy. And in the context of this study, we saw a median PFS of 5.6 months, and there did seem to be a tail on the curve when you looked at the 12-month PFS rate with belzutifan. It was 33.7% compared to 17.6% with everolimus. And then when we look at the response rate, it was higher with belzutifan on the order of 22-23%, and very low with everolimus, as we've previously seen. I think one of the Achilles heels of this regimen is the primary PD rate, which was 34% when used in later line. There are multiple studies that are testing belzutifan in combination across the treatment landscape. So, we have LITESPARK-011, which is looking at the combination of belzutifan plus lenvatinib in the second-line setting. We've got the MK-012 [LITESPARK-012] study, which is looking at belzutifan in various combinations in the frontline setting. So there is a combination with IO plus belzutifan. And so this is also being looked at in that context. And then we also have the LITESPARK-022 study, which is looking at pembrolizumab with belzutifan in the adjuvant setting. So there's a series of studies that will be exploring belzutifan really across the treatment landscape. Many of these studies in combination. Additionally, there are other HIF2α inhibitors that are being developed. We have casdatifan, which is another very potent HIF2α inhibitor. You know, I think pharmacologically, these are different agents. There's a different half-life, different dosing. What is going to be the recommended phase 3 dose for both agents, the EPO suppression levels, the degree of EPO suppression, and sustainability of EPO suppression is very different. So, I think we've seen data from casdatifan from the ARC-20 trial from monotherapy with a respectable response rate, over 30%, primary PD rate hovering just around 10%.  And then we've also seen data of the combination of casdatifan with cabozantinib as well that were recently presented this year. And that agent is also being tested across the spectrum of RCC. It's being looked at in combination with cabozantinib in the PEAK-1 study, and actually just at the KCRS (Kidney Cancer Research Summit), we saw the unveiling of the eVOLVE-RCC trial, which is going to be looking at a volrustomig, which is a PD-1/CTLA-4 inhibitor plus casdatifan compared to nivo-ipi in the frontline setting.  So, we're going to see some competition in this space of the HIF2α inhibitors. I think when we think of mechanism of action in that these are very potent, not a lot of off-target activity, and they target a driver mutation in the disease. And that driver mutation happens very early in the pathogenesis. These are going to be positioned much earlier in the treatment landscape. Dr. Pedro Barata: All these studies, as you're saying, look really promising. And when we talk about them, you mentioned a lot of combinations. And to me, when I think of these agents, it makes a lot of sense to combine because there's not a lot of overlapping toxicities, if you will. But perhaps for some of our listeners, who have not used HIF2α inhibitors in practice yet, and they might be thinking about that, what can you tell us about the safety profile? How do you present it to your patients, and how do you handle things like hypoxia or anemia? How do you walk through the safety profile and tolerability profile of those agents like belzutifan? Dr. Rana McKay: I think these drugs are very different than your traditional TKIs, and they don't cause the classic symptoms that are associated with traditional TKIs that many of us are very familiar with like the rash, hand-foot syndrome, hypertension, diarrhea. And honestly, these are very nuanced symptoms that patients really struggle with the chronicity of being on a chronic daily TKI. The three key side effects that I warn patients about with HIF2α inhibitors are: (1) fatigue; (2) anemia; and (3) hypoxia and dysregulation in the ability to sense oxygen levels. And so, many of these side effects - actually, all of them - are very dose-dependent. They can be very well-managed. So, we can start off with the anemia. I think it's critically important before you even start somebody on belzutifan that you are optimizing their hemoglobin and bone marrow function. Make sure they don't have an underlying iron deficiency anemia. Make sure they don't have B12 or folate deficiency. Check for these parameters. Many patients who have kidney cancer may have some hematuria, other things where there could be some low-level blood loss. So, make sure that those are resolved or you're at least addressing them and supplementing people appropriately. I monitor anemia very closely every 3 to 4 weeks, at least, when people start on these medications. And I do initiate EPO, erythropoietin, should the anemia start to worsen. And I typically use a threshold of around 10g/dL  for implementing utilization of an EPO agent, and that's been done very safely in the context of the early studies and phase 3 studies as well. Now, with regards to the hypoxia, I think it's also important to make sure that you're selecting the appropriate individual for this treatment. People who have underlying COPD, or even those individuals who have just a very high burden of disease in their lung, lymphangitic spread, pleural effusions, maybe they're already on oxygen - that's not an ideal candidate for belzutifan. Something that very easily can be done in the clinic before you think about initiating somebody on this treatment, and has certainly been integrated into some of the trials, is just a 6-minute walk test. You know, have the patient walk around the clinic with one of the MAs, one of the nurses, put the O2 sat on [measuring oxygen saturation], make sure they're doing okay. But these side effects, like I said, are very dose-dependent. Typically, if a patient requires, if the symptoms are severe, the therapy can be discontinued and dose reduced. The standing dose is 120 mg daily, and there's two dose reductions to 80 mg and 40 mg should somebody warrant that dose modification. Dr. Pedro Barata: This is relatively new, right? Like, it was not that we're used to checking oxygen levels, right? In general, we're treating these patients, so I certainly think there's a learning curve there, and some of the points that you highlight are truly critical. And I do share many of those as well in our practice. Since I have you, I want to make sure we touch base on antibody-drug conjugates as well. It's also been a hot area, a lot of developments there. When I think of urothelial carcinoma and renal cell carcinoma, I see it a little bit different. I think perhaps in urothelial carcinoma, antibody-drug conjugates, or ADCs, are somewhat established already. You already mentioned enfortumab vedotin. I might ask you to expand a little bit on that. And then in renal cell carcinoma, we have some ADCs as well that you include in your chapter, and that I would like you to tell us what's coming from that perspective. So, tell us a little bit about how do you see ADCs in general for GU tumors, particularly UC and RCC? Tell us a little bit about the complexity or perhaps the challenges you still see. At the same time, tell us about the successes. Dr. Rana McKay: Stepping back, let's just talk about like the principles and design of ADCs. So, most ADCs have three components. There's a monoclonal antibody that typically targets a cell surface antigen, which is conjugated by a linker, which is the second component, to a payload drug. And typically, that payload drug has been chemotherapy, whether it be topoisomerase or whether it be MMAE or other chemotherapeutic. We can start in the RCC space. There's been multiple antibody-drug conjugates that have been tested. There's antibody-drug conjugates to CD70, which is expressed on clear cell RCC. There's been antibody-drug conjugates to ENPP3, which is also expressed on RCC. There's antibody-drug conjugates to CDH6. And they have different payloads, like I said, whether it be topoisomerase I or other microtubule inhibitors. Now, when we think about kidney cancer, we don't treat this disease with chemotherapy. This disease is treated with immunotherapy. It is treated with treatments that target the VEGF pathway and historically has not been sensitive to chemo. So, I think even though the targets have been very exciting, we've seen very underwhelming data regarding activity, and in some context, seen increased toxicity with the ADCs. So, I think we need to tread lightly in the context of the integration and the testing of ADCs in RCC. We just came back from the KCRS meeting, and there was some very intriguing data about a c-Kit ADC that's being developed for chromophobe RCC, which is, you know, a huge unmet need, these variant tumors that really lack appropriate therapeutics. But I just caution us to tread lightly around how can we optimize the payload to make sure that the tumor that we're treating is actually sensitive to the agent that's targeting the cell kill. So, that's a little bit on the ADCs in RCC. I still think we have a long way to go and still in early testing. Now, ADCs for UC are now the standard of care. I think the prototypical agent, enfortumab vedotin, is a nectin-4-directed ADC that's conjugated to an MMAE payload and was the first ADC approved for advanced urothelial, received accelerated approval following the EV-201 trial, which was basically a multicenter, single-arm study that was investigating EV in cisplatin-ineligible patients with advanced urothelial carcinoma, and then ultimately confirmed in the EV-301 study as well. And so, that study ended up demonstrating the support superiority of EV from an overall survival standpoint, even PFS standpoint. Building on that backbone is the EV-302 study, which tested EV in combination with pembrolizumab versus platinum-based chemotherapy in the frontline setting. And that was a pivotal, landmark study that, like I said, has displaced platinum therapy as a frontline treatment for people with advanced urothelial carcinoma. And when we think about that study and the median overall survival and just how far we've come in urothelial cancer, the median OS with EV-pembro from that trial was 31 and a half months. I mean, that's just incredible. The control arm survival was 16 and a half months. The hazard ratio for OS, 0.47. I mean this is why when this data was presented, it was literally a standing ovation that lasted for several minutes because we just haven't seen data that have looked that good. And there are other antibody-drug conjugates that are being tested. We've all been involved in the saga with sacituzumab govitecan, which is a trophoblast cell surface antigen 2 (Trop-2) targeted ADC with a topoisomerase I payload. It was the second ADC to receive approval, but then that approval was subsequently withdrawn when the confirmatory phase 3 was negative, the TROPiCS-04 trial. So, approval was granted based off of the TROPHY-U-01, single-arm, phase 2 study, demonstrating a response rate of around 28% and a PFS of, you know, about 5 and a half months. But then failure to show any benefit from an OS standpoint. And I think there's a lot of controversy in the field around whether this agent still has a role in advanced urothelial carcinoma. And I think particularly for individuals who do not have molecular targets, like they're not HER2-amplified or have HER2-positivity or FGFR or other things like that. Dr. Pedro Barata: Fantastic summary, Rana. You were talking about the EV, and it came to mind that it might not be over, right, for the number of ADCs we use in clinical practice in the near future. I mean, we've seen very promising data for ADC against the HER2, right, and over-expression. It also can create some challenges, right, in the clinics because we're asking to test for HER2 expression. It's almost like, it's not exactly the same to do it in breast cancer, but it looks one more time that we're a little bit behind the breast cancer field in a lot of angles. And also has vedotin as a payload. Of course, I'm referring to disitamab vedotin, and there's very elegant data described by you in your review chapter as well. And it's going to be very interesting to see how we sequence the different ADCs, to your point as well. So, before we wrap it up, I just want to give you the opportunity to tell us if there's any area that we have not touched, any take-home points you'd like to bring up for our listeners before we call it a day. Dr. Rana McKay: Thank you so much. I have to say, you know, I was so excited at ASCO this year looking at the GU program. It was fantastic to see the progress being made, novel therapeutics that really there's a tremendous excitement about, not just in RCC and in UC, but also in prostate cancer, thinking about the integration of therapies, not just for people with refractory disease that, even though our goal is to improve survival, our likelihood of cure is low, but also thinking about how do we integrate these therapies early in the treatment landscape to enhance cure rates for patients, which is just really spectacular. We're seeing many of these agents move into the perioperative setting or in combination with radiation for localized disease. And then the special symposium on biomarkers, I mean, we've really come a long, long way. And I think that we're going to continue to evolve over the next several years. I'm super excited about where the field is going in the treatment of genitourinary malignancies. Dr. Pedro Barata: Oh, absolutely true. And I would say within the Annual Meeting, we have outstanding Educational Sessions. And just a reminder to the listeners that actually that's where the different teams or topics for the Educational Book chapters come from, from actually the educational sessions from ASCO. And your fantastic chapter is an example of that, right, focusing on advanced GU tumors. So, thank you so much, Rana, for taking the time, sharing your insights with us today on the podcast. It was a fantastic conversation as always. Dr. Rana McKay: My pleasure. Thanks so much for having me, Dr. Barata. Dr. Pedro Barata: Of course.  And thank you to our listeners for your time today. You will find the link to the article discussed today in the transcript of this episode. I also encourage you to check out the 2025 ASCO Educational Book. You'll find an incredible wealth of information there. It's free, available online, and you'll find, hopefully, super, super important information on the key science and issues that are shaping modern oncology, as we've heard from Dr. McKay and many other outstanding authors. So, thank you, everyone, and I hope to see you soon. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:        Dr. Pedro Barata @PBarataMD Dr. Rana McKay @DrRanaMcKay Follow ASCO on social media:        @ASCO on X (formerly Twitter)        ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:     Dr. Pedro Barata: Stock and Other Ownership Interests: Luminate Medical Honoraria: UroToday Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck  Dr. Rana McKay: Consulting or Advisory Role: Janssen, Novartis, Tempus, Pfizer, Astellas Medivation, Dendreon, Bayer, Sanofi, Vividion, Calithera, Caris Life Sciences, Sorrento Therapeutics, AVEO, Seattle Genetics, Telix, Eli Lilly, Blue Earth Diagnostics, Ambrx, Sumitomo Pharma Oncology, Esiai, NeoMorph, Arcus Biosciences, Daiichi Sankyo, Exelixis, Bristol Myers Squibb, Merck, Astrazeneca, Myovant Research Funding (Inst.): Bayer, Tempus, AstraZeneca, Exelixis, Bristol Myers Squibb, Oncternal Therapeutics, Artera    

07-09-2025- The Gospel of Luke- Luke 12:35-48- Mark Wood by RCC

Message from Aaron Lewis on September 7, 2025

Video Block Double-click here to add a video by URL or embed code. Learn more Presentation Life Group Notes DEVOTIONAL (TO COME) PermalinkHugh PearceProverbsfalseThe Way of Wisdom

Thursday, 4 September 2025   But He answered and said to the one who told Him, “Who is My mother and who are My brothers?” Matthew 12:48   “And answering, He said to the ‘telling Him', ‘Who, she is, My mother, and who, they are, My brothers?'” (CG).   In the previous verse, Jesus was told that His mother and brothers were outside seeking to speak with Him. Matthew next records, “And answering, He said to the ‘telling Him', ‘Who, she is, My mother, and who, they are, My brothers?'”   The words seem curiously distant, as if Jesus is removing Himself from the family relationship He was born into. This is not the case. It needs to be remembered who He has been speaking to. Earlier, it said –   “And all the multitudes were amazed and said, ‘Could this be the Son of David?' 24 Now when the Pharisees heard it they said, ‘This fellow does not cast out demons except by Beelzebub, the ruler of the demons.'” Matthew 12:23, 24   Since then, He has been speaking to them concerning their accusation, carefully refuting it. It said in verse 46, “While He was still talking to the multitudes...” This tells us that it has been an ongoing speech. The scribes and Pharisees had accused Jesus not only of not being the Messiah (the Son of David), but that He was in league with the devil.   Therefore, in being presented with the note of His mother and brothers coming to speak to Him, He is taking the opportunity to further refute the accusation of the Pharisees. That will be seen in verse 12:50 as the chapter closes out.   Life application: Various charges against both Jesus and Mary have been made because of the words in the se final verses of the chapter. Some may accuse Jesus of not living in accordance with the command to honor His mother according to the law. Such an accusation is unfounded. The gospels bear witness to His concern for her, even to His dying words on the cross.   Likewise, there are those who take Jesus' words to extremes, not even hinted at concerning Mary. Without addressing their inane comments directly due to their ridiculous nature, the reason for their words comes back to contempt for Roman Catholicism's inexcusable fixation on Mary in other ways.   Because of RCC doctrine, and in order to start a tit for tat war of words, Mary as a person is purposefully diminished and disparaged. This intentional poking serves no purpose except to stir up animosity between parties. If there was any substance to what they were saying, they would include the brothers of Jesus in their comments as well.   The words Jesus conveys, when properly understood, are exactly how the Savior of the world would be expected to respond. They form another strong contradiction to the accusations of the scribes and Pharisees. They also support the notion that those who are in a right standing with God are not those who trust in their own merits, like these accusers. Rather, they will reveal those who are favored by the Messiah in the redemptive process that God has set forth.   Lord God, thank You for the wisdom that is carefully revealed in Your word that can, if we analyze it properly, impart that wisdom to us as well. May we carefully consider Scripture as Your word, intended to build us up in the knowledge of who You are and what You are doing in the world as You guide us back to Yourself. Amen.  

31-08-2025-Being a Gospel Strange People-Rigby Wallace by RCC

31-08-2025-Rejoice-Bryce Biggs by RCC

Message from Rodney Bartlett on August 31, 2025

In this episode host Marc Goldberg interviews Rogue Community College (RCC) and Southern Oregon University (SOU) graduate Jahna Thompson, Rogue Community College president, Dr. Randy Weber and Director, Postsecondary Success at The Ford Family Foundation, Denise Callahan. Jahna emphasizes the value of strong faculty mentorship and advising from her student experience at both Rogue Community College and SOU with a unique lens of having taught in her field of study at both institutions as a faculty/professor over the past year. She elaborates on her academic journey that began taking GED prep classes at RCC and after completing her Bachelor's and Master's degrees, she is currently pursuing a PhD in Immunology & Infectious Disease at Washington State University.President Weber reflects on Jahna's interview and describes specific college efforts through responsive programming, student supports and community partnerships that have helped increase enrollment and improve retention and completion outcomes for students, including those who enter the college taking adult education courses. Denise highlights the Foundation's impactful postsecondary education work across Oregon,  particularly in rural communities, through Foundation investments, scholarships and research. She describes how the Foundation's work supporting over 1000 postsecondary education students annually across Oregon through scholarships helps inform the organization's policy and research work and shares more on the recently released Oregon by the Numbers report by the Foundation that offers a detailed profile for each of Oregon's 36 counties. The All In: Student Pathways Forward podcast is a part of Oregon's participation in the National Skills Coalition SkillSPAN network.

Matt Slick Live (Live Broadcast of 08/27/2025) is a production of the Christian Apologetics Research Ministry (CARM). Matt answers questions on topics such as: The Bible, Apologetics, Theology, World Religions, Atheism, and other issues! You can also email questions to Matt using: info@carm.org, Put "Radio Show Question" in the Subject line! Answers will be discussed in a future show. Topics Include: Matt Announces The Release of New WebSite Articles—Priesthood Table of The RCC and EO, Levels of Reward in Heaven/The Need to Equip The Saints so We Can Reach The Lost/ Caller Wants to Know if Matt Has a "Go To" Bible Verse to Live By/Which Translation Does He Prefer, and Why there are Currently so Many/ Matt Discusses the Current State of Artificial Intelligence for Websites/Email Question—A "Oneness" Dress Issue/ Can God Destroy a "Spirit?"/Why Eternal "Punishment" Requires Experience/ Matt Discusses Problems with "Soul Sleep" and "Annihilationism"/How this Relates to The Dual Nature of Jesus/A "Oneness" Problem Examined/ 1 Peter 2:8—Does God Appoint Disobedience?/ August 27, 2025

We continue our conversation with Mike Atkins and David McDermott, discussing IO-based combination therapy in RCC.

24-08-2025- Rich towards God- part 5- Luke 12:22-34- Mark Wood by RCC

Message from Terry Williams on August 24, 2025

In this episode, Josh and Michael take a trip down a road less travelled by both patients and researchers, and examine the evidence (or lack thereof) of non-clear cell renal cell cancer, a less common cluster of siblings to the much better established clear cell RCC. Treatment is on very similar patterns, so their studies today involve a lot of immunotherapy with a smattering of tyrosine kinase inhibitors.Studies discussed in this episodeKEYNOTE-B61Checkmate 920For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Dr. Sumanta (Monty) Pal and Dr. Arielle Elkrief discuss the clinical relevance of the gut microbiome in cancer immunotherapy and the importance of antibiotic stewardship, as well as interventions currently being explored to treat gut dysbiosis and optimize immunotherapy response. TRANSCRIPT Dr. Sumanta (Monty) Pal: Hi everyone, I'm Dr. Monty Pal, welcoming you to the ASCO Daily News Podcast. I'm a medical oncologist. I'm a professor and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles.  Today we're here to discuss one of my favorite topics, which is the gut microbiome. It's almost hard to avoid the gut microbiome nowadays if you look at medical literature within oncology. It's an emerging phenomenon, but there are a couple of individuals that I would really define as pioneers in the field. And one of them is actually with me today, Dr. Arielle Elkrief, to discuss the clinical relevance of the gut microbiome, particularly amongst patients receiving immunotherapy, although I imagine our conversation today will take many twists and turns. Arielle is an assistant professor and clinician scientist in the Department of Oncology at the University of Montreal, and she is co-director of the CHUM Microbiome Center there.  FYI for the listeners, we have our full disclosures in the transcript of this episode.  Arielle, thank you so much for joining us today. Dr. Arielle Elkrief: Thanks so much, Monty. This is going to be amazing. Dr. Sumanta (Monty) Pal: Well, I have to tell you what sort of inspired me to bring you on as a guest. It was one of many things, but it was this really terrific ASCO Educational [Book] article that you wrote. Now, I have to tell you, I've read all the articles sort of cover to cover in the book, and they're always a wonderful primer, so if our audience is studying for board research or something of that sort, it's a terrific resource to go through. I have to tell you, this piece on the gut microbiome that you wrote is nothing short of a masterpiece. If you read this cover to cover, it's actually going to give you, I think, a sense of the current state and future state of the field. I wanted to start by just sort of beginning with sort of the origin story for a lot of this, which is this association between the gut microbiome and immunotherapy response. This takes us back several years to this pivotal series of papers in Science. Maybe you could walk our audience through that. Dr. Arielle Elkrief: Absolutely. Well, thank you so much for your kind words about the ASCO [Educational] Book. It was a team effort with a lot of key opinion leaders in the field, so I'm really glad to learn that you've liked it.  Moving backwards in terms of how we came to understand that the gut microbiome is essential to priming a response to cancer immunotherapy actually goes back to 2015 and seminal papers that looked at what happens when we take mice that are germ-free mice that have never been exposed to a microbiome. These are mice that are born by cesarean section and essentially live in a bubble. And when we give those mice tumors and treat them, in the first papers with anti-CTLA-4 treatment, we realized that these antibodies don't work at all. And that was the first observation that the presence of a gut microbiome was essential to mounting an anti-cancer immune response. When we supplemented those same mice with beneficial bacteria or feces from responder patients, we were able to restore the response to immunotherapy. And so those were really the first preclinical observations that made us understand the critical role of the microbiome in immunotherapy response. Moving a little bit in the future, we examined the fecal microbiome composition using shotgun metagenomic sequencing in different cohorts of patients with solid tumors, namely lung cancers, kidney cancers, and also skin tumors like melanoma, and found that patients who responded to immunotherapy had a distinct microbiome that was characterized by beneficial bacteria compared to patients who experienced resistance to immunotherapy that had a dysbiotic or diseased microbiome. Dr. Sumanta (Monty) Pal: So, you know, it's interesting, these techniques that we're using to sequence the gut, they're a little bit different. So I wonder if you can give the audience a quick primer on these techniques that you're so well versed in, shotgun metagenomic sequencing, 16S rRNA sequencing. If you had to describe this in 30 seconds, which is a tall task, how would you do that? Dr. Arielle Elkrief: That's a tall task. Much of what we know about the microbiome initially came from a technique called 16S rRNA sequencing. This is a technique that amplifies the 16S region and basically tells you at the genus level what's going on at the level of bacterial composition. This technique is fast, relatively cheap, and can be performed on a laptop computer, which is excellent. The problem is that it's prone to a lot of technical variations. Different primers might give you different results, and you're really limited at the genus resolution. You can't get a good resolution in terms of species, and we're learning that different species from the same genus might have different physiological properties, and the same thing goes at the strain level. So when we really zone in and look at inter-species changes, we're seeing that these actually have specific functions in the host. So that brings us to metagenomic sequencing, which is a whole genome sequencing, next-generation sequencing based method that looks at the whole composition and gives you information not only on bacteria, but you might also get fungal and viral properties. You can zoom in on the strain level. You can also get functional output, so we can examine what the metabolic properties of specific species or strains might look like. The negative aspects of shotgun metagenomic sequencing is that it takes a lot of computational power in order to analyze the results and it might take a little bit longer. And certainly, within the clinical setting, not something that's feasible yet.  And that brings us to more novel point-of-care biomarker tools that we've collaborated in developing along with Dr. Laurence Zitvogel and Dr. Lisa Derosa at Gustave Roussy, that learning from the shotgun metagenomics results designed a probe using quantitative PCR which looks for this specific bacteria we know to be important and developed a ratio of harmful bacteria to beneficial bacteria. This is called the TOPOSCORE, and it actually is able to predict quite nicely the response to immunotherapy using a stool sample and a really good turnaround time of almost 72 hours. Dr. Sumanta (Monty) Pal: That was a perfect overview and a lot of information in a short amount of time. It also makes you take out your high school biology textbooks, doesn't it, to understand that the bacterial ribosome, right, is a different size and shape, and that's what we're sequencing here. But these techniques I think are incredibly important, and I'm glad you actually discussed this, this RT-PCR based strategy of calculating the TOPOSCORE. It lends itself to this phenomenon of dysbiosis, and I think for our audience, that's going to be an important term to understand as time goes on. There's the normal healthy gut and then there's this phenomenon of dysbiosis, which is, I guess, simply put, an unhealthy gut. But tell us about, you know, how often you see dysbiosis in a cancer patient, maybe versus a normal healthy adult. Dr. Arielle Elkrief: So, I think we can split up your question into two parts. One is we know from cohort studies and population level-based studies that the microbiome of patients with cancer is distinct from healthy patients or healthy people. And we know that because of the global composition. We also think that there are diversity metrics that lend themselves to being described as dysbiotic. But we do know that the microbiome of people with cancer is distinct from healthy volunteers. That's the first point.  In terms of how frequently dysbiosis occurs in patients with cancer, it's not very well defined. We know that even among healthy people, there is a certain level of dysbiosis. Laurence in her talk mentioned that to be about 10% to 20%. And the other fascinating component is that when we're thinking about dysbiosis and the cancer associated microbiome, in terms of the species that are enriched, it's quite striking that a lot of these dysbiotic or negative bacteria are also found to be enriched in patients with metabolic disease, like cardiovascular disease, for example. And so it's unclear if dysbiosis is the cause or consequence, but there definitely seems to be a general pattern of disease when looking at the microbiome compared to healthy people. Dr. Sumanta (Monty) Pal: That's interesting. So, I'll tell you, my second favorite portion of your article, and I'll tell you my favorite portion as well in the context of this podcast, but my second favorite part was the section around antibiotic stewardship. You know, the utilization of antibiotics in a very pragmatic fashion amongst our patients. Can you describe why that's so critical in the context of the microbiome? Dr. Arielle Elkrief: Antibiotics can disrupt the gut microbiome composition. We know this from mouse studies, but also cohort studies of patients that are exposed to antibiotics. And most importantly, we know that patients who are exposed to antibiotics, either before or during the immunotherapy period, have significantly worse progression-free survival and overall survival to immunotherapy. And this is true for immunotherapy in the monotherapy setting, but also when combined with chemotherapy. What's striking is that when we look at patients who are just treated with chemotherapy, we don't see the negative outcome of antibiotics on outcome and progression-free survival and overall survival, suggesting that the negative impact of antibiotics on outcomes is really specific to immunotherapy backbones. The other important point is that this negative signal is maintained even after adjusting for standard prognostic variables in the specific malignancies that we're looking at. And then most importantly, at the mechanistic level, we were able to actually pinpoint the mechanism behind this antibiotic related dysbiosis. And we see this with a bloom of negative bacteria which induces a loss of MAd-CAM, which is an endothelial gut checkpoint immune marker, and that causes an efflux of immunosuppressive T cells, which are usually in the gut, to go straight into the tumor where they make the tumor unamenable to an immunotherapy response. And so now we finally have the mechanism as to why antibiotics are harmful and why we need to practice antibiotic stewardship. Dr. Sumanta (Monty) Pal: And just to be clear for the audience, I mean, if a patient needs antibiotics, they need antibiotics. But perhaps it just suggests that, and we have, I suppose, this predilection as oncologists, just for the minor cold or cough or what have you, we maybe should be a little bit more cognizant of whether or not antibiotics are truly necessary. Is that fair? Dr. Arielle Elkrief: Absolutely. So what we're advocating for is antibiotic stewardship, and this is the clear recommendation that we can make. So that means confirming a bacterial infection. If it's there and antibiotics are indicated, to choose the most narrow spectrum for the shortest course and constantly re-evaluate the indication of antibiotics. And of course, we need to work with our colleagues in infectious diseases who've done incredible work in antibiotic stewardship. And all along this process we also need to be mindful of other medications and polypharmacy, such as proton pump inhibitors or narcotics, for example, we think that these other medications which are frequently prescribed in our cancer population can also potentially have negative impacts on the microbiome and immunotherapy response. Dr. Sumanta (Monty) Pal: I think that's a terrific summary and big guidance for the audience.  I promised you I'd tell you my favorite part of your article, and this is this huge table. I think the table is two and a half pages long, if I remember correctly, but it's an awesome table, and I highly recommend our audience to check this out. It lists literally every therapeutic trial for the microbiome under the sun. And so it begins with the approach of fecal microbiota transplant, which I'm going to ask you to tell us about in a second, but it also hinges on a lot of really cool sort of novel therapies, live bacterial products, mixes of different microbial products. Maybe take us through this whole approach of FMT (fecal microbiota transplantation). I actually wasn't aware of the dozens of trials that you listed there in this space. It seems like it's a very active area of research. Dr. Arielle Elkrief: Definitely. So, as you alluded to, FMT or fecal microbiota transplantation is the most well studied and direct way to modify the patient's microbiome. This technique aims to replace the patient's dysbiotic microbiome with that of a healthy microbiome, either from a healthy donor volunteer that's been heavily screened, or from a patient who experienced response to immunotherapy. And, as three landmark studies so far that have been published demonstrated the potential of FMT to reduce primary resistance or secondary resistance to immunotherapy, and this has been in melanoma.  We also recently reported on the results of our FMT-LUMINate trial, which looked at patients with lung cancer and melanoma. Once again, FMT, when combined with immunotherapy was safe and led to a higher proportion of responses than we would normally expect.  We're now also looking at randomized trials that have come out. So the first being the TACITO trial in kidney cancer, which compared FMT plus pembrolizumab and axitinib to placebo in patients with RCC, and again, FMT was safe and feasible and also led to an increased progression-free survival at one year, meeting the study's primary endpoint.  And so, so far, there's a wealth of data really showing the promise of FMT when combined with immunotherapy, and we're now in the process of conducting larger randomized trials, including in melanoma with the CCTG (Canada Cancer Trials Group) in our ME17 or Canbiome2 trial, where we're going to be enrolling 128 patients with metastatic melanoma to receive FMT and standard of care immunotherapy compared to standard of care immunotherapy alone. Dr. Sumanta (Monty) Pal: You're very humble, so I've got to highlight for our audience. This was a mega grant that Arielle received to fund really the largest prospective exploration of FMT that will exist to date. So I'm really excited about that. I wish this was something we could participate in stateside.  Before we jump into the other approach, which is live bacterial products and mixes thereof, where do you see FMT going? I think that one of the perceived challenges with FMT is that it's hard to implement, right? You need to have a really robust framework when it comes to gastroenterology, the preparation's challenging. Is there a way to envision FMT use being more generalized? Dr. Arielle Elkrief: Those are great questions. So we're lucky in Canada to work with pioneers in FMT, Michael Silverman, Saman Maleki, and John Lenehan in London, Ontario, who had this really robust FMT healthy donor screening program, which literally screens for every pathogen under the sun, and we haven't had any problems with feasibility or implementing FMT in Canada. But I think that once we're going to hopefully start doing larger scale, randomized phase three studies, that we might run into problems with scalability. And I think also with regards to reproducibility, and that's the feedback that we're getting from some regulatory authorities, especially at the level of the FDA, where there are some concerns around inter- and intra-donor variability because, of course, we can't guarantee that every fecal sample is going to be the same. So that has really pushed the field to think about other strategies, such as live biotherapeutic products which take modified FMT or bacteria from stools from either healthy donors or from responder patients and basically turn them into drugs that are regulated as drugs and can then be studied in the context of investigational new drugs or products. Dr. Sumanta (Monty) Pal: I like this and, you know, I do think that there's a future for it. We just have to kind of put our heads together and figure out how to get over all of these logistical hurdles, but, you know, I agree, I think your group and others have demonstrated, especially with this trial that you're fanning out all throughout Canada, that it can potentially be done.  This is a topic that could probably go on for another couple of hours, right, especially based on the size of the table that you put together in this brilliant article, but tell us about live bacterial products or LBPs, as we call them these days. What's the current status, what's the future there? And maybe I'll give you less than two minutes here, although again, I realize it's a two-hour topic. Dr. Arielle Elkrief: You're probably better suited to speak about that because you've been one of the pioneers in terms of this. So we can think about LBPs in terms of single strain organisms, like CBM588 for an example, which your group did some amazing work in showing that, in a randomized setting, that this led to better responses than we would expect compared to just work with controls. We also know that LBPs can have multiple strains, up to 30. We're collaborating with a company called Cannabis Bioscience that is actually working on much larger communities of consortia. And so we're really excited about the direction that that's taking in terms of taking these LBPs and developing them from the drug perspective. In addition to LBPs, we know that there are other ways that we can change the microbiome, notably prebiotics, which are compounds which can have a beneficial impact on the microbiome. And one of these is camu camu, which I know your group is leading a clinical trial looking at camu camu and kidney cancer, and we're excited to see how that compares to FMT or LBPs, because that might be a potentially scalable alternative. Dr. Sumanta (Monty) Pal: That's awesome. What a terrific overview, and that was less than two minutes. I don't know how you did it. That's terrific.  Arielle, this has been such an insightful conversation. I just want to thank you for, again, a terrific article in the ASCO Educational Book. I highly recommend all of our listeners to go there and check it out, and also for sharing all these terrific insights on the podcast today. Dr. Arielle Elkrief: Thank you so much, Monty. Dr. Sumanta (Monty) Pal: And thanks to our listeners, too. If you value the insights that you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks, everyone. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:    Dr. Sumanta (Monty) Pal  @montypal Dr. Arielle Elkrief Follow ASCO on social media:     @ASCO on Twitter    ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures:    Dr. Sumanta (Monty) Pal:   Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview  Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical  Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis  Dr. Arielle Elkrief: Honoraria: AstraZenica, Bristol-Myers Squibb, Merck, EMD Serono Consulting or Advisory Role: Bristol-Myers Squibb Research Funding (Inst.): Kanvas Bioscience, AstraZeneca, Merck Other Relationship: Royal College of Surgeons and Physicians of Canada, Cedar's Cancer Center (Henry R. Shibata Fellowship), Canadian Institutes of Health Research (CIHR)

The fathers of IO therapy in RCC - Michael Atkins and David McDermott - join us to take a tour through IO development in RCC over the last 20 years.

Message from Terry Williams on August 17, 2025

On hour three of the Big Show with George Rusic, Matty Rose, and Garret Vander Ploeg, they are joined by Jon Morosi. They breakdown the Toronto Blue Jays recent series against the Chicago Cubs, the pitching, Max Scherzer, John Schneider's expiring contract, the quality of the bullpen, Shane Bieber, AAA rehabs, Wade Boggs and his superstitions. The guys close out the segment talking about what meats are the best.(29:57) Surprise Guess Stuart Skinner joins the home of the Calgary Flames on Sportsnet. He shares his thoughts going into the Legends of Hockey Golf Tournament at the Rogers Charity Classic. Before answering questions about his offseason work, superstitions, and what he enjoys about the RCC. Before the end of the hour Scott McCarron, who's teeing off at the RCC later today joins the show. Talking about his experience between the PGA and Champions tours and how he's been preparing for the tournament this weekend.  The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the position of Rogers Media Inc. or any affiliate.

On hour one of the Big Show Matt Rose, George Rusic, and GVP talk about Matty's game in round two of the Pro-Ams at the RCC, the wildest shots in golf, and Intern Raygan Johnson's last day in the studio. A special guest pops in to share his thoughts on golf, then the guys talk about Johnny Unitas's broken jaw and hardcore career.(26:29) The Morning Report with Matty Rose, bringing you the latest in sports. The Calgary Flames new center ice, Blue Jays wrap up their series with the Cubs, Matt goes over the rest of the contenders in MLB, the PGA weeks away from the FedEx Cup, the Rogers Charity Classic here in Calgary, Week 11 of the CFL, and the Calgary Surge Playoff update.  The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the position of Rogers Media Inc. or any affiliate.

On hour one of the Big Show Patrick Dumas and Matt Rose are down at Canyon Meadows Golf Course getting ready to open up the Rogers Charity Classic. Today is Pro-Am round one and the fellas break it down, before Dumas gets a welcome back to the show after his vacation to Guatemala City. (22:14) The Morning Report with Patrick Dumas has all the latest in sports. Including, the Blue Jays game against the Cubs, Week 11 in the CFL with the Stamps on bye, continuing NFL camps, the Hlinka-Gretzky Cup in Czechia and Slovakia, and more RCC, before wrapping it up with some local sports. The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the position of Rogers Media Inc. or any affiliate.

On hour two of the Big Show with Patrick Dumas and Matt Rose bring in Chris Dornan, the PR director of the RCC! The three discuss some of the tournament history, it's impact on the community, what to look forward to this weekend, and the excitement behind the Legends of Hockey tournament.   (20:41) The Calgary Stampeders head coach, Dave Dickenson, takes time from the teams bye week to talk with Patrick and Matt. The trio talk the Stamps most recent game, a win over Winnipeg, Vernon Adams Jr., and the defensive competition. Wes Martin, a RCC Golfer Calgary Qualifier, who shot a nine under to get into the tournament at Highwood Country Club. He talks with Patrick and Rose about that stellar score, how he did it, how he got to this point in his golfer career, and how he plans to tackle the RCC. The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the position of Rogers Media Inc. or any affiliate.

On hour three of the Big Show with Patrick Dumas and Matt Rose, the President of the PGA Champions Tour Miller Brady talks RCC. What he loves about the event, what Canyon Meadows offers, the golfers competing, and how the tour would prepare for Tiger Woods, if he decided to join the Champions Tour. (10:21) Corey Pavin joins the show, sharing his experience of his cameo on the new Happy Gilmore 2 film, how it happened, what it was like, and all the fun he had on set. After the guys are done discussing Corey's stint in Hollywood, the conversation moves to the RCC. What Corey enjoys whilst he's in the city, the Champions tour, how he's been playing, how he practices to win, and what he is most looking forward to this weekend. The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the position of Rogers Media Inc. or any affiliate.

On hour two of the Big Show with Rusic and Rose, Sportsnet's Adam Stanley joins the guys. Sharing his Ryder Cup predictions, thoughts on Canadian golfer Corey Conners, Tommy Fleetwood, Justin Rose, all of this heading into the RCC weekend. The textline rounds out the segment with listeners hole-in-one stories.(24:47) At the bottom of the hour the boys pick it up with some early NHL power rankings. Going over the top ten which include, the Dallas Stars, Edmonton Oilers, and Vegas Golden Knights, before diving down the rankings for your Calgary Flames. The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the position of Rogers Media Inc. or any affiliate.

On hour three of the Big Show with Rusic and Rose, Brent Krahn comes in, talking goalies in the show, the to early power rankings, and his thoughts on the Connor Zary situation. (24:41) Dustin Wolf talks his golf game nearing the Legends of Hockey Golf Tournament at the RCC this weekend, his offseason training regimen, and takes some time to answer questions from the fans. The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the position of Rogers Media Inc. or any affiliate.

In this episode, listen to Kelly Romo, PharmD, BCOP; and Shauna Kraft, PharmD, BCOP, share their takeaways from a live webinar on available emerging subcutaneous immunotherapy options for patients with cancer including:Basic mechanism of action and role of hyaluronidase in subcutaneous immunotherapy formulation and available dosing/schedulesAvailable pharmacodynamics/pharmacokinetics, efficacy, and safety data for subcutaneous immunotherapy formulationsCurrent and potential models for administration of subcutaneous immunotherapy in the inpatient setting and day-to-day considerationsPresenters:Kelly Romo, PharmD, BCOPManager, Oncology Medical Drug Management and Customer InitiativesBlue Cross Blue Shield MichiganDetroit, MichiganShawna Kraft, PharmD, BCOPClinical Pharmacist, SpecialistMichigan Medicine, Rogel Cancer CenterClinical Associate ProfessorUniversity of Michigan College of PharmacyAnn Arbor, MichiganResources:Consolidate your learning with a recording from an on-demand webcast, download the slides associated with this discussion, or read an expert text module or commentary on this topic. 

In this episode, listen to Kelly Romo, PharmD, BCOP; and Shauna Kraft, PharmD, BCOP, share their takeaways from a live webinar on available emerging subcutaneous immunotherapy options for patients with cancer including:Basic mechanism of action and role of hyaluronidase in subcutaneous immunotherapy formulation and available dosing/schedulesAvailable pharmacodynamics/pharmacokinetics, efficacy, and safety data for subcutaneous immunotherapy formulationsCurrent and potential models for administration of subcutaneous immunotherapy in the inpatient setting and day-to-day considerationsPresenters:Kelly Romo, PharmD, BCOPManager, Oncology Medical Drug Management and Customer InitiativesBlue Cross Blue Shield MichiganDetroit, MichiganShawna Kraft, PharmD, BCOPClinical Pharmacist, SpecialistMichigan Medicine, Rogel Cancer CenterClinical Associate ProfessorUniversity of Michigan College of PharmacyAnn Arbor, MichiganResources:Consolidate your learning with a recording from an on-demand webcast, download the slides associated with this discussion, or read an expert text module or commentary on this topic. 

August 11, 2025 - - Tyler Cormeny & Rev. Courtney Carson of RCC joined Byers & Co to talk about O’Shea and Richland’s collaboration with the Minority Trades Network. Listen to the podcast now!See omnystudio.com/listener for privacy information.

Message from Terry Williams on August 10, 2025

Welcome back to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by world-renowned medical oncologist Dr. Monty Pal from the City of Hope. Together, they dived deep into the management of side effects associated with tyrosine kinase inhibitors (TKIs) and HIF-2 alpha inhibitors used in treating renal cell carcinoma (RCC). Episode Highlights: • Understanding TKIs and HIF-2 Inhibitors: A discussion on the available oral treatment options for RCC, including cabozantinib, lenvatinib, and axitinib. • Dosing Strategies: Insights on starting doses, titration, and the importance of managing side effects without compromising quality of life. • Common Side Effects: hypertension, diarrhea, fatigue, and how they relate to the class effect of these medications. • Clinical Pearls: Dr. Pal shared valuable tips on managing toxicities, including the use of treatment breaks and supportive care strategies. • Second-Line Treatments: A look at tivozanib and belzutifan, including their unique side effects and management strategies. Join us as we emphasized the importance of maintaining quality of life for patients undergoing treatment for metastatic RCC.  Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to check out our other episodes for more insights on treatment algorithms, conference highlights, and challenging cases from the community.

出演：小林康秀さん（RCC中国放送 アナウンサー） 2025年8月6日（水）「FrontLine Session」より 発信型ニュース・プロジェクト「荻上チキ・Session」 ★月～金曜日　17:00～20:00　TBSラジオで生放送 パーソナリティ：荻上チキ、南部広美 番組HP：⁠荻上チキ・Session⁠ 番組メールアドレス：⁠ss954@tbs.co.jp⁠ 番組Xアカウント：⁠@Session_1530⁠ ハッシュタグは ⁠#ss954 Learn more about your ad choices. Visit megaphone.fm/adchoices

Message from Jim Lewis on August 3, 2025

Dr. Corsi talks with Mike McCormick, former stenographer for Joe Biden and author of The Case to Impeach and Imprison Joe Biden, about the Obama/Biden administrations' teaming up with Pope Francis and Cardinal Theodore McCarrick and other elements of the Deep State and Deep Church to promote the woke agenda and to fortify the efforts of the globalist elite. McCormick will discuss this subject in-depth in his next book.Visit The Corsi Nation website: https://www.corsination.comIf you like what we are doing, please support our Sponsors:MyVitalC https://www.thetruthcentral.com/myvitalc-ess60-in-organic-olive-oil/Swiss America: https://www.swissamerica.com/offer/CorsiRMP.phpGet Dr. Corsi's new book, The Assassination of President John F. Kennedy: The Final Analysis: Forensic Analysis of the JFK Autopsy X-Rays Proves Two Headshots from the Right Front and One from the Rear, here: https://www.amazon.com/Assassination-President-John-Kennedy-Headshots/dp/B0CXLN1PX1/ref=sr_1_1?crid=20W8UDU55IGJJ&dib=eyJ2IjoiMSJ9.ymVX8y9V--_ztRoswluApKEN-WlqxoqrowcQP34CE3HdXRudvQJnTLmYKMMfv0gMYwaTTk_Ne3ssid8YroEAFg.e8i1TLonh9QRzDTIJSmDqJHrmMTVKBhCL7iTARroSzQ&dib_tag=se&keywords=jerome+r.+corsi+%2B+jfk&qid=1710126183&sprefix=%2Caps%2C275&sr=8-1Join Dr. Jerome Corsi on Substack: https://jeromecorsiphd.substack.com/Visit The Truth Central website: https://www.thetruthcentral.comGet your FREE copy of Dr. Corsi's new book with Swiss America CEO Dean Heskin, How the Coming Global Crash Will Create a Historic Gold Rush by calling: 800-519-6268Follow Dr. Jerome Corsi on X: @corsijerome1Become a supporter of this podcast: https://www.spreaker.com/podcast/corsi-nation--5810661/support.

Episode 308 hosts Dr Raquel Amado (Dental Surgeon from Kent, UK) and Dr Anoob Pakkar-Hull (Cosmetic Physician from London, UK) In our 'Masterclass Series' we host global experts to teach us about fillers, bio-stimulators, bio-remodellers, polynucleotides, exosomes and other products. (For toxin insights, check out our other mini-series, 'The Tox Talks') In Chapter 7 we discuss various different combination treatments that are commonly used in regenerative aesthetics. Raquel and Anoob discuss their experiences and insights with various treatment modalities and cocktails of microtoxin, the various biostimulators, polynucleotides, PRP and exosomes.  Our conversation also highlights their upcoming RCC meeting that will be held in the Azores. RCC will showcase experts for in-depth lectures and debates about these innovative treatments. The event is non-sponsored and aims to foster open, unbiased discussions and on the efficacy and safety of these advanced regenerative therapies. 00:00 Introduction 01:29 IA Competition Details 02:13 Introducing Dr. Raquel Amado and Dr Anoob Pakkar-Hull 07:07 Microtoxin and Combination Therapies 08:47 Exploring Regenerative Aesthetics 15:04 Microtoxin and NCTF: A Powerful Combination 22:50 Biostimulators and Bio Remodelers 32:26 PRP: Experiences and Insights 36:14 Challenges with PRP Consistency 36:49 Equipment and Variability in PRP 37:46 Historical and Current Uses of PRP 38:18 Combining PRP with Other Treatments 40:19 Introduction to Polynucleotides 40:56 Mechanisms and Benefits of Polynucleotides 43:57 Combining Polynucleotides with Other Treatments 50:27 Exosomes: Sources and Uses 53:18 Patient Communication and Treatment Customization 59:15 Debating the Efficacy of Regenerative Treatments 01:04:15 Future of Regenerative Medicine and Conferences 01:08:02 RCC Conference Overview and Invitation   FIND OUT MORE ABOUT REGENERA COLLECTIVE CONFERENCE & BUY TICKETS - IA LISTENERS GET 15% off BY USING THE CODE IA15! CHECK OUT OUR PATREON & GET A 7 DAYS FREE TRIAL! BROWSE OUR IA OFFERS FOR DISCOUNTS & SPECIALS YOUR A BRAND OR COMPANY & WANT TO WORK WITH US APPLY TO BE A GUEST ON OUR PODCAST CONTACT US  

When is Y90 the right treatment for metastatic disease? Join Drs. Tyler Sandow, Zach Berman and host Kavi Krishnasamy in the conclusion of Dosimetry University where they discuss the complexities of treating different variations of metastatic disease and review how they've approached complicated cases with Y90. --- SYNPOSIS The interventional oncologists first outline the types of metastases that they treat, including colorectal, lung, cholangiocarcinoma, breast, gastric, RCC, and melanoma. The doctors then discuss the potential for Y90 to provide palliative relief by reducing tumor-related pain. The conversation also covers key differences between treating liver-dominant and liver-only disease, along with their algorithm for patients not on systemic chemotherapy.The episode then covers advanced concepts in Y90, such as sub-ablative dosing, the possibility of creating an abscopal effect, and how radiation thresholds change depending on treatment goals. They outline their approach to partition dosimetry, using SPECT/CT to calculate tumor-to-normal ratios, and explain how they modify particle counts and microsphere activity, using flow augmentation based on tumor vascularity. Additional discussion includes the impact of mutation status, prior lines of chemotherapy, and tumor response criteria like RECIST 1.1 and mRECIST. The experts conclude with a case series that illustrates decision-making around when to consider Y90, thermal ablation, TACE, or alternative approaches—even in complex cases like sphincter of Oddi dysfunction. The session underscores the nuanced nature of advanced dosimetric techniques and the evolving landscape of interventional oncology. --- TIMESTAMPS 00:00 - Introduction 01:30 - Types of Metastases Treated with Y9002:50 - Liver-Dominant vs. Liver-Only Disease 07:20 - Sub-Ablative Dosing and the Abscopal Effect09:55 - Tips for Partition Dosimetry 15:30 - Clinical Factors in Treatment Planning23:50 - Choosing Ablation, Resection, or Y90 for mCRC30:27 - Case Series: Colorectal Metastases, Biliary Complications, and more46:00 - Final Thoughts: The Evolving Field --- RESOURCES RECIST 1.1 and mRECIST Criteria:https://pmc.ncbi.nlm.nih.gov/articles/PMC9161105/ COLLISION Trial:https://ascopubs.org/doi/10.1200/JCO.2024.42.17_suppl.LBA3501 BackTable Episode on COLLISION Trial:https://www.youtube.com/watch?v=NQLKcv1BRVM FOXFIRE, SIRFLOX, FOXFIRE-Global:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30457-6/fulltext

Today, we have a guest message from Rick Dickinson, RCC's campus administrator and lead pastor of Refuge Church Malin. This message comes from our evening sessions during our mission trip to Paisley. Enjoy and be challenged by this powerful word! Support the show

Today's episode we will cover 2025 updates for localized renal cell carcinoma (RCC) with Dr. Tom Powles and Dr. Brian Rini from the urologic oncology podcast Uromigos! We will discuss risk factors, the presentation, staging, and treatment options. 

This Sunday, we get to hear from a very good friend of mine, Gentry Morris. Gentry is the Lead Pastor at Reston Community Church in Northern Virginia where he serves the RCC family through preaching, teaching, and helping people find deep hope in the gospel of Jesus. Before coming to RCC, Gentry served as a pastor in Washington state and in church planting ministry in Belfast, Northern Ireland. He also has been involved in worship ministry and writing songs for the local church. Gentry plans to preach from Philippians 1:1-11 on finding joy and contentment in our lives, rooted in the gospel, and extending through us in generosity.  ------------------------------------------- Connect with us on Social Media ⁠Website⁠ | ⁠Instagram⁠⁠⁠⁠ | ⁠Threads⁠ | ⁠Facebook⁠⁠⁠⁠ | ⁠Vimeo⁠------------------------------------------- Download our App⁠Apple App Store⁠ | ⁠Google Play Store⁠

Message from Trace Kendrick on July 27, 2025

Keen observers questioned why Pop Benedict XVI really "stepped down" from his post prematurely to make room for the current Pope Francis (Jorge Mario Bergoglio) in 20113. While Pope Benedict was maligned by the mainstream media Pope Francis was heralded by the same MSM members as an Obama-like rockstar, bringing in a Globalist/Socialist agenda into the Roman Catholic Church. While the truth behind the scenes indicates Francis was installed through manipulation by the Obama/Biden administration while the three re-promoted known pedophile Cardinal Theodore McCarrick to international prominence. Together, they worked hard to advance the Globalist Agenda. Hollywood, however, dutifully attempted to Whitewash the controversial Pope Francis installment as a friendly and amicable transition through the Obama-led Netflix service's movie "The Two Popes."Mike McCormick, author of THE CASE TO IMPEACH AND IMPRISOIN JOE BIDEN, and Biden's former stenographer, got to see some of what really happened up close. Mike joins Dr. Jerome Corsi on The Truth Central to talk about it.Visit Mike McCormick's substack here: https://mmccormick.substack.com/p/the-deep-state-hollywood-evil-behindVisit The Corsi Nation website: https://www.corsination.comIf you like what we are doing, please support our Sponsors:MyVitalC https://www.thetruthcentral.com/myvitalc-ess60-in-organic-olive-oil/Swiss America: https://www.swissamerica.com/offer/CorsiRMP.phpGet Dr. Corsi's new book, The Assassination of President John F. Kennedy: The Final Analysis: Forensic Analysis of the JFK Autopsy X-Rays Proves Two Headshots from the Right Front and One from the Rear, here: https://www.amazon.com/Assassination-President-John-Kennedy-Headshots/dp/B0CXLN1PX1/ref=sr_1_1?crid=20W8UDU55IGJJ&dib=eyJ2IjoiMSJ9.ymVX8y9V--_ztRoswluApKEN-WlqxoqrowcQP34CE3HdXRudvQJnTLmYKMMfv0gMYwaTTk_Ne3ssid8YroEAFg.e8i1TLonh9QRzDTIJSmDqJHrmMTVKBhCL7iTARroSzQ&dib_tag=se&keywords=jerome+r.+corsi+%2B+jfk&qid=1710126183&sprefix=%2Caps%2C275&sr=8-1Join Dr. Jerome Corsi on Substack: https://jeromecorsiphd.substack.com/Visit The Truth Central website: https://www.thetruthcentral.comGet your FREE copy of Dr. Corsi's new book with Swiss America CEO Dean Heskin, How the Coming Global Crash Will Create a Historic Gold Rush by calling: 800-519-6268Follow Dr. Jerome Corsi on X: @corsijerome1Become a supporter of this podcast: https://www.spreaker.com/podcast/corsi-nation--5810661/support.

Message from Terry Williams on July 20, 2025

Joining the Exchange are Ruth Swain, Director of RCC's SBDC and Tim Busald, SBDC Business Advisor.

Joining the Exchange are Ruth Swain, Director of RCC's SBDC and Tim Busald, SBDC Business Advisor.

Axel Bex joins the show to discuss trials that he thinks have impacted RCC. We also discuss consolidative approaches, neoadjuvant trials and what can impact an academic career.

Message from Terry Williams on July 13, 2025

Listen as Michael S. Benninger, MD, describes his approach to the diagnosis and management of chronic cough and refractory chronic cough in the context of a clinically relevant case.PresenterMichael S. Benninger, MDProfessor of Otolaryngology-Head and Neck SurgeryLerner College of MedicineThe Cleveland ClinicPresident, International Association of PhonosurgeryCleveland, OhioLink to full program:https://bit.ly/4kweynG

Message from Terry Williams on July 6, 2025